Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology

09-05-2024 | Non-Hodgkin Lymphoma | REVIEW ARTICLE

The association between primary Sjogren’s syndrome and non-Hodgkin’s lymphoma: a systematic review and meta-analysis of cohort studies

Authors: Narges Ansari, Mansour Salesi

Published in: Clinical Rheumatology

Login to get access

Abstract

Primary Sjögren’s syndrome (pSS), a chronic autoimmune condition, has been associated with an increased risk of several cancers. This study aims to delve into the relationship between pSS and the potential development of non-Hodgkin’s lymphoma (NHL) utilizing an in-depth systematic review and meta-analysis approach. To thoroughly explore the topic, we conducted a thorough examination of the literature, drawing from reputable databases such as ProQuest, PubMed, Web of Science, Cochrane, and Google Scholar. Our data collection spanned until February 8, 2024, with no time limitation. Data were analyzed with Stata 14 software at a significance threshold of p < 0.05. We examined 15 cohort studies encompassing a total of 50,308 individuals from 1997 to 2023. The findings revealed a substantial link between pSS and the risk of NHL, evident across all demographics. Specifically, the standardized incidence ratio (SIR) was generally 8.78 (95% CI 5.51, 13.99), with similar trends observed in both men (SIR, 6.29; 95% CI 1.93, 20.51) and women (SIR, 9.60; 95% CI 5.89, 15.63). Additionally, the SIR (10.50 (95% CI 7, 15.75)), HR (2.82 (95% CI 1.28, 6.18)), and OR (10.50 (95% CI 3.04, 36.28)) indices further supported this association. Furthermore, the risk of non-NHL associated with pSS was noticeable across different age groups of 40–49 years (SIR, 30.13; 95% CI 14.62, 62.08), 50–59 years (SIR, 9.12; 95% CI 5.13, 16.19), and 60–69 years (SIR, 9; 95% CI 4.68, 17.32). pSS substantively augments the likelihood of NHL manifestation. It notably impacts females and those in earlier stages of adulthood with more acuity than males and older cohorts.
Appendix
Available only for authorised users
Footnotes
1
Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
 
2
International prospective register of systematic reviews.
 
3
Medical Subject Headings.
 
Literature
1.
Duan W, Jiang F, Ouyang S, Yin W, Zeng Q, Yang H (2023) Lymphoplasmapheresis versus plasma exchange in severe myasthenia gravis: a retrospective cohort study. Front Neurol 14:1212868PubMedPubMedCentralCrossRef
2.
Luo W, Tian L, Tan B, Shen Z, Xiao M, Wu S et al (2022) Update: innate lymphoid cells in inflammatory bowel disease. Dig Dis Sci 67(1):56–66PubMedCrossRef
3.
Rajaei E, Jalali MT, Pezeshki SMS, Rezaeeyan H, Maniati M, Elyasi M et al (2020) Dose HLA-B5, 7, 8, 27, and 51 antigens associated to behcet’s disease? A study in Southwestern Iran. Curr Rheumatol Rev 16(2):120–124PubMedCrossRef
4.
Rajaei E, Shahbazian N, Rezaeeyan H, Mohammadi AK, Hesam S, Zayeri ZD (2019) The effect of lupus disease on the pregnant women and embryos: a retrospective study from 2010 to 2014. Clin Rheumatol 38:3211–3215PubMedCrossRef
5.
Narvaez J, Sanchez-Fernandez SA, Seoane-Mato D, Diaz-Gonzalez F, Bustabad S (2020) Prevalence of Sjögren’s syndrome in the general adult population in Spain: estimating the proportion of undiagnosed cases. Sci Rep 10(1):10627PubMedPubMedCentralCrossRef
6.
Brito-Zerón P, Baldini C, Bootsma H, Bowman SJ, Jonsson R, Mariette X et al (2016) Sjögren syndrome. Nat Rev Dis Primers 2(1):1–20CrossRef
7.
Leone M, Alunno A, Cafaro G, Valentini V, Marcucci E, Bartoloni E et al (2017) The clinical spectrum of primary Sjögren’s syndrome: beyond exocrine glands. Reumatismo 69(3):93–100PubMedCrossRef
8.
Nocturne G, Mariette X (2013) Advances in understanding the pathogenesis of primary Sjögren’s syndrome. Nat Rev Rheumatol 9(9):544–556PubMedCrossRef
9.
Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F et al (2015) Epidemiology of primary Sjögren’s syndrome: a systematic review and meta-analysis. Ann Rheum Dis 74(11):1983–1989PubMedCrossRef
10.
11.
12.
Theander E, Manthorpe R, Jacobsson L (2004) Mortality and causes of death in primary Sjögren’s syndrome: a prospective cohort study. Arthritis Rheum 50(4):1262–1269PubMedCrossRef
13.
Retamozo S, Gheitasi H, Quartuccio L, Kostov B, Corazza L, Bové A et al (2016) Cryoglobulinaemic vasculitis at diagnosis predicts mortality in primary Sjögren syndrome: analysis of 515 patients. Rheumatology (Oxford) 55(8):1443–1451PubMedCrossRef
14.
Shahjahani M, Abroun A, Saki N, Bagher Mohammadi SM, Rezaeeyan H (2020) STAT5: from pathogenesis mechanism to therapeutic approach in acute leukemia. Lab Med 51(4):345–351PubMedCrossRef
15.
Zintzaras E, Voulgarelis M, Moutsopoulos H (2005) The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 165(20):2337–2344PubMedCrossRef
16.
Pan L, Feng F, Wu J, Fan S, Han J, Wang S et al (2022) Demethylzeylasteral targets lactate by inhibiting histone lactylation to suppress the tumorigenicity of liver cancer stem cells. Pharmacol Res 181:106270PubMedCrossRef
17.
Tabatabaee S, Bahrami F, Janahmadi M (2021) The critical modulatory role of spiny stellate cells in seizure onset based on dynamic analysis of a neural mass model. Front Neurosci 15:743720PubMedPubMedCentralCrossRef
18.
Shen W, Pei P, Zhang C, Li J, Han X, Liu T et al (2023) A polymeric hydrogel to eliminate programmed death-ligand 1 for enhanced tumor radio-immunotherapy. ACS Nano 17(23):23998–24011PubMedCrossRef
19.
Tian Z, Zhang Y, Zheng Z, Zhang M, Zhang T, Jin J et al (2022) Gut microbiome dysbiosis contributes to abdominal aortic aneurysm by promoting neutrophil extracellular trap formation. Cell host & microbe 30(10):1450–63.e8CrossRef
20.
Wu W, Li H, Wang Z, Dai Z, Liang X, Luo P et al (2024) The tertiary lymphoid structure-related signature identified PTGDS in regulating PD-L1 and promoting the proliferation and migration of glioblastoma. Heliyon 10(1):e23915PubMedCrossRef
21.
22.
Gan Y, Li L, Zhang L, Yan S, Gao C, Hu S et al (2018) Association between shift work and risk of prostate cancer: a systematic review and meta-analysis of observational studies. Carcinogenesis 39(2):87–97PubMedCrossRef
23.
24.
Liang W, Liu H, Zeng Z, Liang Z, Xie H, Li W et al (2023) KRT17 promotes T-lymphocyte infiltration through the YTHDF2–CXCL10 axis in colorectal cancer. Cancer Immunol Res 11(7):875–894PubMedPubMedCentralCrossRef
25.
Aslan B, Öğüt T, Erbasan F, Dilbil M, Çelik E, Terzioğlu M et al (2022) The risk of cancer in patients with primary sjögrensyndrome; a single-center study from Turkey. Turk J Med Sci 52(3):587–595PubMedCrossRef
26.
Goulabchand R, Malafaye N, Jacot W, Viel P, Morel J, Lukas C et al (2021) Cancer incidence in primary sjögren’s syndrome: data from the French hospitalization database. Autoimmun Rev 20(12):102987PubMedCrossRef
27.
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA; PRISMA-P Group (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4(1):1. https://​doi.​org/​10.​1186/​2046-4053-4-1
28.
Peterson J, Welch V, Losos M, Tugwell PJOOHRI (2011) The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hosp Res Inst 2(1):1–12
29.
Higgins JPT, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558PubMedCrossRef
30.
Kang J, Kim H, Kim J, Choi S, Jung S, Jang E et al (2020) Risk of malignancy in Korean patients with primary sjögren’s syndrome. Int J Rheum Dis 23(9):1240–1247PubMedCrossRef
31.
Mayer M, Martinic M, Reihl-Crnogaj M, Anic B (2023) The risk of developing non-Hodgkin lymphoma and the mortality rate in primary sjögren’s syndrome: a single-centre, retrospective cohort study. Rheumatol Int 43(11):2031–2036PubMedCrossRef
32.
Isik O, Yazici A, Cefle A (2022) The relationship between malignancy and primary sjogren’s syndrome; single center results. Acta Medica Nicomedia 5(2):49–55CrossRef
33.
Wang L, Wang W, Lin C, Lin S, Shieh C (2020) Bidirectional relationship between primary sjögren syndrome and non-Hodgkin lymphoma: a nationwide Taiwanese population-based study. J Rheumatol 47(9):1374–1378PubMedCrossRef
34.
Ahn J, Hwang J, Seo G (2020) Risk of non-Hodgkin’s lymphoma and thyroid cancer in primary Sjögren’s syndrome measured using the Korean Health Insurance Claims Database. Clin Exp Rheumatol 38:40–6PubMed
35.
Brom M, Moyano S, Gandino I, Scolnik M, Soriano E (2019) Incidence of cancer in a cohort of patients with primary sjögren syndrome in Argentina. Rheumatol Int 39(10):1697–1702PubMedCrossRef
36.
Brito-Zerón P, Kostov B, Fraile G, Caravia-Durán D, Maure B, Rascón F et al (2017) Characterization and risk estimate of cancer in patients with primary sjögren syndrome. J Hematol Oncol 10(1):90PubMedPubMedCentralCrossRef
37.
Chiu Y, Chung C, Lin K, Lin C, Chen J, Chen H et al (2017) Predictable biomarkers of developing lymphoma in patients with sjögren syndrome: a nationwide population-based cohort study. Oncotarget 8(30):50098–50108PubMedPubMedCentralCrossRef
38.
Abrol E, González-Pulido C, Praena-Fernández J, Isenberg D (2014) A retrospective study of long-term outcomes in 152 patients with primary sjögren’s syndrome: 25-year experience. Clin Med 14(2):157–164CrossRef
39.
Johnsen S, Brun J, Gøransson L, Småstuen M, Johannesen T, Haldorsen K et al (2013) Risk of non-Hodgkin’s lymphoma in primary sjögren’s syndrome: a population-based study. Arthritis Care Res (Hoboken) 65(5):816–821PubMedCrossRef
40.
Weng M, Huang Y, Liu M, Lu T (2012) Incidence of cancer in a nationwide population cohort of 7852 patients with primary sjögren’s syndrome in Taiwan. Ann Rheum Dis 71(4):524–527PubMedCrossRef
41.
Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson L (2006) Lymphoma and other malignancies in primary sjögren’s syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 65(6):796–803PubMedCrossRef
42.
Kauppi M, Pukkala E, Isomäki H (1997) Elevated incidence of hematologic malignancies in patients with sjögren’s syndrome compared with patients with rheumatoid arthritis (Finland). Cancer Causes Control 8(2):201–204PubMedCrossRef
43.
Liang Y, Yang Z, Qin B, Zhong R (2014) Primary sjögren’s syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis 73(6):1151–1156PubMedCrossRef
44.
Zhong H, Liu S, Wang Y, Xu D, Li M, Zhao Y et al (2022) Primary sjögren’s syndrome is associated with increased risk of malignancies besides lymphoma: a systematic review and meta-analysis. Autoimmun Rev 5:103084CrossRef
45.
Ekström Smedby K, Vajdic C, Falster M, Engels E, Martínez-Maza O, Turner J et al (2008) Autoimmune disorders and risk of non-hodgkin lymphoma subtypes: a pooled analysis within the interlymph consortium. Blood 111(8):4029–4038PubMedPubMedCentralCrossRef
46.
Ekström Smedby K, Hjalgrim H, Askling J, Chang E, Gregersen H, Porwit-MacDonald A et al (2006) Autoimmune and chronic inflammatory disorders and risk of non-hodgkin lymphoma by subtype. J Natl Cancer Inst 98(1):51–60CrossRef
47.
Lazarus M, Robinson D, Mak V, Møller H, Isenberg D (2006) Incidence of cancer in a cohort of patients with primary sjogren’s syndrome. Rheumatology (Oxford) 45(8):1012–1015PubMedCrossRef
48.
Zhang W, Feng S, Yan S, Zhao Y, Li M, Sun J et al (2010) Incidence of malignancy in primary sjögren’s syndrome in a Chinese cohort. Rheumatology (Oxford) 49(3):571–577PubMedCrossRef
49.
Shi X, Wallach J, Ma X, Rogne T (2024) Autoimmune diseases and risk of non-Hodgkin lymphoma: a Mendelian randomisation study. medRxiv 73(1):17
Metadata
Title
The association between primary Sjogren’s syndrome and non-Hodgkin’s lymphoma: a systematic review and meta-analysis of cohort studies
Authors
Narges Ansari
Mansour Salesi
Publication date
09-05-2024
Publisher
Springer International Publishing
Published in
Clinical Rheumatology
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-024-06993-6
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits